Javier Torres-Roca
Overview
Explore the profile of Javier Torres-Roca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parikh N, Yamoah K, Johnstone P, Torres-Roca J, Pow-Sang J, Fernandez D, et al.
Cancer Control
. 2025 Jan;
32:10732748251317691.
PMID: 39876663
Prostate Artery Embolization (PAE) is a novel minimally invasive angiographic technique that has been used effectively to treat men with lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH)....
2.
Sandoval M, Rishi A, Latifi K, Grass G, Torres-Roca J, Rosenberg S, et al.
Cancer Control
. 2024 Aug;
31:10732748241270595.
PMID: 39206515
Objectives: Stereotactic body radiotherapy (SBRT) is widely used for localized prostate cancer and implementation of MR-guided radiotherapy has the advantage of tighter margins and improved sparing of organs at risk....
3.
Naghavi A, Bryant J, Kim Y, Weygand J, Redler G, Sim A, et al.
BMC Cancer
. 2024 Apr;
24(1):437.
PMID: 38594603
Background: Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response (FPR ≥ 95%) from RT is...
4.
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Scarborough J, Eschrich S, Torres-Roca J, Dhawan A, Scott J
NPJ Precis Oncol
. 2023 Apr;
7(1):38.
PMID: 37076665
Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine...
5.
Awasthi S, Grass G, Torres-Roca J, Johnstone P, Pow-Sang J, Dhillon J, et al.
J Natl Cancer Inst
. 2022 Sep;
114(12):1656-1664.
PMID: 36053178
Background: Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African...
6.
Fink A, DeRenzis A, Awasthi S, Jahan N, Johnstone P, Pow-Sang J, et al.
Cancer Med
. 2022 Jul;
12(2):1869-1877.
PMID: 35796421
Participation in cancer research trials by minority populations is imperative in reducing disparities in clinical outcomes. Even with increased awareness of the importance of minority patient inclusion in clinical research...
7.
Sandoval M, Youssef I, Latifi K, Grass G, Torres-Roca J, Rosenberg S, et al.
J Clin Med
. 2021 Aug;
10(15).
PMID: 34362179
Background: The use of stereotactic body radiation therapy (SBRT) is widely utilized for treatment of localized prostate cancer. Magnetic-resonance-guided radiotherapy (MRgRT) was introduced in 2014 and has recently been implemented...
8.
Parikh N, Keshishian E, Manley B, Grass G, Torres-Roca J, Boulware D, et al.
J Vasc Interv Radiol
. 2021 Apr;
32(7):1053-1061.
PMID: 33794373
Purpose: To assess the effectiveness and safety of prostatic artery embolization (PAE) on lower urinary tract symptoms (LUTS) in the setting of localized prostate cancer (PCa). Materials And Methods: This...
9.
Grisaru-Tal S, Itan M, Grass D, Torres-Roca J, Eschrich S, Gordon Y, et al.
Oncoimmunology
. 2021 Jan;
10(1):1859732.
PMID: 33457078
Eosinophils are bone marrow-derived granulocytes that display key effector functions in allergic diseases. Nonetheless, recent data highlight important roles for eosinophils in the tumor microenvironment (TME). Eosinophils have been attributed...
10.
Yamoah K, Awasthi S, Mahal B, Zhao S, Grass G, Berglund A, et al.
Eur Urol
. 2020 Dec;
81(4):325-330.
PMID: 33303244
Grade group 4 and 5 (GG-45) prostate cancer (PCa) patients are at the highest risk of lethal outcomes, yet lack genomic risk stratification for prognosis and treatment selection. Here, we...